Therefore, in the present study, we first examined the Mer expression in both tumoral and stromal compartments by using tissue microarrays (TMA) containing a relatively large amount of NSCLC samples (150 cases) and repeated the findings in freshly harvested NSCLC samples (30 cases) by using immunohistochemistry and western blotting, and then correlated the findings with clinicopathological features of patients. This evidence concerns the gene MERTK and non-small cell lung carcinoma.